1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 8, 2, 10 and 1 respectively.
Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Allergic Conjunctivitis - Overview
- Allergic Conjunctivitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Allergic Conjunctivitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Allergic Conjunctivitis - Companies Involved in Therapeutics Development
- Accolade Pharmaceuticals LLC
- Aldeyra Therapeutics Inc
- Alexion Pharmaceuticals Inc
- ALK-Abello AS
- Allakos Inc
- Boehringer Ingelheim International GmbH
- Clevexel Pharma SA
- Faes Farma SA
- IACTA Pharmaceuticals Inc
- Intas Pharmaceuticals Ltd
- JW Pharmaceutical Corp
- Kissei Pharmaceutical Co Ltd
- Nanomerics Ltd
- NicOx SA
- Ocular Therapeutix Inc
- OKYO Pharma Ltd
- Oyster Point Pharma Inc
- Quark Pharmaceuticals Inc
- RAPT Therapeutics Inc
- Satellos Bioscience Inc
- SIFI SpA
- Siolta Therapeutics Inc
- Sylentis SAU
- Vanda Pharmaceuticals Inc
- Wuhan Yicheng Biotechnology Co Ltd
- Allergic Conjunctivitis - Drug Profiles
- bertilimumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- bilastine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- birch pollen allergen extract - Drug Profile
- Product Description
- Mechanism Of Action
- cetirizine hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CVXL-0074 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- epinastine hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IC-265 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IC-270 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KCE-210 - Drug Profile
- Product Description
- Mechanism Of Action
- ketotifen SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lipidated tacrolimus - Drug Profile
- Product Description
- Mechanism Of Action
- lirentelimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NM-134 - Drug Profile
- Product Description
- Mechanism Of Action
- OC-103 - Drug Profile
- Product Description
- Mechanism Of Action
- OKYO-0101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PH-006 - Drug Profile
- Product Description
- Mechanism Of Action
- PRT-2761 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- QPI-1020R - Drug Profile
- Product Description
- Mechanism Of Action
- reproxalap - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RPT-193 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis - Drug Profile
- Product Description
- Mechanism Of Action
- STMC-103H - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SYL-116011 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VSJ-110 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Yipiwutai - Drug Profile
- Product Description
- Mechanism Of Action
- Zafi-2 - Drug Profile
- Product Description
- Mechanism Of Action
- Allergic Conjunctivitis - Dormant Projects
- Allergic Conjunctivitis - Discontinued Products
- Allergic Conjunctivitis - Product Development Milestones
- Featured News & Press Releases
- Mar 01, 2022: Nicox’s partner Ocumension obtains positive phase 3 clinical trial results for ZERVIATE in China
- Feb 01, 2022: Aldeyra Therapeutics announces publication of phase 2 clinical trial of reproxalap in allergen chamber model
- Jan 05, 2022: Nicox European patent seals ZERVIATE major market coverage to 2030
- Jul 05, 2021: Nicox to receive $2 million from Ocumension Therapeutics as advance milestone payment under ZERVIATE agreement
- Apr 27, 2021: Aldeyra Therapeutics achieves statistical significance for primary endpoint and all secondary endpoints in phase 3 INVIGORATE clinical trial of Reproxalap in allergic conjunctivitis
- Apr 26, 2021: Aldeyra Therapeutics schedules conference call and webcast to announce top-line results from the phase 3 INVIGORATE clinical trial
- Dec 30, 2020: Nicox’s partner Ocumension Therapeutics initiates ZERVIATE phase 3 clinical trial in China
- Oct 26, 2020: Vanda Pharmaceuticals receives FDA approval to proceed with Investigational New Drug VSJ-110 for allergic conjunctivitis
- Oct 22, 2020: Aldeyra to present new Reproxalap data from phase 2 clinical trial in allergic conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting
- Sep 22, 2020: Nicox’s ZERVIATE receives IND approval in China
- May 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the digital EAACI Annual Congress 2020
- May 11, 2020: Allakos announces a presentation of antolimab in patients with severe allergic conjunctivitis at the 2020 ASCRS Virtual Annual Meeting
- Mar 30, 2020: Eyevance Pharmaceuticals launches ZERVIATE in the United States
- Feb 24, 2020: Aldeyra Therapeutics to provide update on late-stage clinical development pipeline at 2020 Research & Development Day
- Jan 22, 2020: Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Allergic Conjunctivitis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, 2022
- Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, 2022
- Allergic Conjunctivitis - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Allergic Conjunctivitis - Pipeline by ALK-Abello AS, 2022
- Allergic Conjunctivitis - Pipeline by Allakos Inc, 2022
- Allergic Conjunctivitis - Pipeline by Boehringer Ingelheim International GmbH, 2022
- Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, 2022
- Allergic Conjunctivitis - Pipeline by Faes Farma SA, 2022
- Allergic Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2022
- Allergic Conjunctivitis - Pipeline by Intas Pharmaceuticals Ltd, 2022
- Allergic Conjunctivitis - Pipeline by JW Pharmaceutical Corp, 2022
- Allergic Conjunctivitis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
- Allergic Conjunctivitis - Pipeline by Nanomerics Ltd, 2022
- Allergic Conjunctivitis - Pipeline by NicOx SA, 2022
- Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, 2022
- Allergic Conjunctivitis - Pipeline by OKYO Pharma Ltd, 2022
- Allergic Conjunctivitis - Pipeline by Oyster Point Pharma Inc, 2022
- Allergic Conjunctivitis - Pipeline by Quark Pharmaceuticals Inc, 2022
- Allergic Conjunctivitis - Pipeline by RAPT Therapeutics Inc, 2022
- Allergic Conjunctivitis - Pipeline by Satellos Bioscience Inc, 2022
- Allergic Conjunctivitis - Pipeline by SIFI SpA, 2022
- Allergic Conjunctivitis - Pipeline by Siolta Therapeutics Inc, 2022
- Allergic Conjunctivitis - Pipeline by Sylentis SAU, 2022
- Allergic Conjunctivitis - Pipeline by Vanda Pharmaceuticals Inc, 2022
- Allergic Conjunctivitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
- Allergic Conjunctivitis - Dormant Projects, 2022
- Allergic Conjunctivitis - Dormant Projects, 2022 (Contd..1)
- Allergic Conjunctivitis - Discontinued Products, 2022
- Number of Products under Development for Allergic Conjunctivitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accolade Pharmaceuticals LLC
- Aldeyra Therapeutics Inc
- Alexion Pharmaceuticals Inc
- ALK-Abello AS
- Allakos Inc
- Boehringer Ingelheim International GmbH
- Clevexel Pharma SA
- Faes Farma SA
- IACTA Pharmaceuticals Inc
- Intas Pharmaceuticals Ltd
- JW Pharmaceutical Corp
- Kissei Pharmaceutical Co Ltd
- Nanomerics Ltd
- NicOx SA
- Ocular Therapeutix Inc
- OKYO Pharma Ltd
- Oyster Point Pharma Inc
- Quark Pharmaceuticals Inc
- RAPT Therapeutics Inc
- Satellos Bioscience Inc
- SIFI SpA
- Siolta Therapeutics Inc
- Sylentis SAU
- Vanda Pharmaceuticals Inc
- Wuhan Yicheng Biotechnology Co Ltd
